Recently published Chronic Kidney Disease Market Insights report includes a comprehensive understanding of current treatment practices, chronic kidney disease emerging drugs, market share of ...

The chronic kidney disease market growth is being driven by the rising global prevalence of diabetes, hypertension, and aging populations. Increasing awareness and earlier diagnosis are expanding ...

A variety of potentially life-saving medications are available online, including Insulin Lispro, Farxiga and Tikosyn. There are also name-brand GLP-1 weight-loss drugs and medications treating ...

TrumpRx.gov is now live in California, offering discounted cash‑pay prices on 40+ meds. Here’s how it works and who benefits most.

The imbalance between pharma’s investment in brand advertising versus corporate and public affairs has become a strategic liability amid the most challenging regulatory conditions the drug industry ...

TrumpRX is a new federal website launched in early Feb. 2026 that provides access to discounted cash prices on certain brand-name prescription drugs.

Treating kidney disease GLP-1s show higher risk than SGLT2 inhibitors in kidney outcomes, but lower albuminuria and mortality rates.

AstraZeneca AZN reported fourth-quarter 2025 core earnings of $2.12 per share, which missed the Zacks Consensus Estimate of ...

While proven to help, primary care clinicians have been slow to use the drugs once considered only for patients with diabetes.

Reflecting confidence in durable cash generation, the board declared a full-year 2025 dividend of $3.20 per share. Management also signaled its intent to lift the annual dividend to $3.30 in 2026, ...

The American Heart Association released its 2026 Heart Disease and Stroke Statistics Update, and a reminder that heart disease remains a challenge.